The main objective of this study is to evaluate the clinical efficacy of the drug Sominex (Valeriana officinalis L., 40 mg, 30 mg Crataegus oxyacantha L. and Passiflora incarnata L. 50 mg) manufactured by the Laboratory EMS S / A, compared to placebo in improving sleep efficiency, based on the response of the sleep quality questionnaire (MSQ) and polysomnographic parameters described below: * Latency to onset of sleep; * Total time of sleep; * Rapid eye movement (REM) sleep latency; * Duration of REM sleep
Verify the effectiveness of the drug Sominex compared to placebo based on the improvement of the following parameters measured by the following validated scales: * Anxiety; * Daytime sleepiness; Will also be assessed secondary to drug safety testing for the occurrence, type, frequency and intensity of adverse events during treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
100
Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
Excipient
LAL Clinica Pesquisa e Desenvolvimento Ltda
Valinhos, São Paulo, Brazil
Improvement in sleep efficiency
Quality of Sleep Questionnaire and the polysomnographic parameters: * Latency to onset of sleep; * Total time of sleep; * REM sleep latency; * Duration of REM sleep;
Time frame: 28 days of treatment.
Improvement of the values obtained by the answers of the questionnaires obtained during the treatment
Scale Hamilton Anxiety (HAM-A); Daytime Sleepiness Scale Epworth; Journal of Sleep
Time frame: 28 days of treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.